Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR-ICE in relapsed/refractory diffuse large B-cell lymphoma
ChiCTR2100049327Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2021
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pomalidomide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: complete response rate and safety. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
pomalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2100049327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049327.